RZLT (Rezolute) Moat Score: 3/10 (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RZLT Rezolute Inc RZLT
34 GF Score
Price $5.09
! 1 Warning Sign
View Full Analysis

What is Rezolute Moat Score?

Rezolute RZLT +9.11% 34 Moat Score is 3 as of Aug. 23, 2026. GuruFocus rates RZLT with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,388 Biotechnology companies, Rezolute ranks better than 75.5% on this metric.

Rezolute has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Rezolute has No Moat: Rezolute Inc has very weak competitive advantages. It lacks market leadership, significant customer switching costs, and valuable intellectual property. The company faces intense competition in the biotech industry and does not benefit from economies of scale or regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Rezolute might have No Moat - Very weak/transient advantages.

Rezolute  (NAS:RZLT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Rezolute Moat Score Related Terms

RZLT vs DNA, EIKN, ARTV: Moat Score Comparison

For the Biotechnology subindustry, Rezolute's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rezolute Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rezolute's Moat Score distribution charts can be found below:

* The bar in red indicates where Rezolute's Moat Score falls into.


RZLT
34GF Score
Rezolute Inc RZLT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Rezolute (RZLT) has a Moat Score of 3 as of Aug. 23, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Rezolute ranks #340 out of 1388 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Rezolute's Moat Score too high?
Rezolute's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Rezolute's value of 3 is 50% above this industry median. Based on the distribution chart, Rezolute ranks #340 out of 1388 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rezolute has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Rezolute's Moat Score compare to DNA and EIKN?
According to the Biotechnology industry distribution chart, Rezolute ranks #340 out of 1388 companies for Moat Score. This places Rezolute in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Rezolute's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,388 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rezolute's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rezolute's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rezolute stock overvalued right now?
Rezolute (RZLT) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Rezolute's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Rezolute (RZLT), the current Moat Score is 3 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rezolute Business Description

Address 275 Shoreline Drive, Suite 500, Redwood City, CA, USA, 94065
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
34GF Score

Get the complete analysis for RZLT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.09
Price